Logo Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows: - revenues from product sales (53.7%); - revenues from collaboration agreements (42.7%): collaboration with Sanofi (74.8% of revenues), Bayer (24.7%) and other (0.5%); - revenues from sales of technology licenses and subcontracted research services (3.6%). At the end of 2024, the group had a portfolio of approximately 40 products in clinical development.
Employees
15,222
More about the company
Trader
Investor
Global
Quality
ESG MSCI
A
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
26
Last Close Price
755.51USD
Average target price
830.04USD
Spread / Average Target
+9.86%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. REGN Stock
  4. ETFs Regeneron Pharmaceuticals, Inc.